Search research articles
Contact Us
Filters
Showing results (181-190 of 197) with videos related to
Page
of 20
Sort By:
BMC Infectious Diseases
|
September 27, 2025
Long-term impact of COVID-19 in patients with lung cancer receiving immune checkpoint inhibitors: a multicenter cohort study during Omicron pandemic
Yajuan Zhang, Yanlin Li, Yamin Zhang, et al.
BMC Medicine
|
February 24, 2023
Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT)
Yuankai Shi, Jianhua Chen, Helong Zhang, et al.
Nature Cancer
|
January 5, 2024
Author Correction: Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC
Caicun Zhou, Ziping Wang, Meili Sun, et al.
Nature Cancer
|
June 15, 2023
Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC
Caicun Zhou, Ziping Wang, Meili Sun, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 7, 2022
Efficacy and Safety of SH-1028 in Patients With EGFR T790M-Positive NSCLC: A Multicenter, Single-Arm, Open-Label, Phase 2 Trial
Anwen Xiong, Shengxiang Ren, Huaimin Liu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 29, 2021
Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study
Xinghao Ai, Yueyin Pan, Jianhua Shi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 6, 2024
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous <i>EGFR</i>-Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial
D Ross Camidge, Jair Bar, Hidehito Horinouchi, et al.
Lancet (London, England)
|
May 29, 2026
Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial
Anwen Xiong, Wenxiu Yao, Wei Zheng, et al.
The Lancet. Oncology
|
June 16, 2025
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial
Caicun Zhou, Ziping Wang, Meili Sun, et al.
Nature Medicine
|
July 11, 2024
Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial
Ying Cheng, Jianhua Chen, Wei Zhang, et al.
Page
of 20
Search research articles
Search
Showing results (181-190 of 197) with videos related to
Sort By:
Page
of 20
BMC Infectious Diseases
|
September 27, 2025
Long-term impact of COVID-19 in patients with lung cancer receiving immune checkpoint inhibitors: a multicenter cohort study during Omicron pandemic
Yajuan Zhang, Yanlin Li, Yamin Zhang, et al.
BMC Medicine
|
February 24, 2023
Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT)
Yuankai Shi, Jianhua Chen, Helong Zhang, et al.
Nature Cancer
|
January 5, 2024
Author Correction: Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC
Caicun Zhou, Ziping Wang, Meili Sun, et al.
Nature Cancer
|
June 15, 2023
Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC
Caicun Zhou, Ziping Wang, Meili Sun, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 7, 2022
Efficacy and Safety of SH-1028 in Patients With EGFR T790M-Positive NSCLC: A Multicenter, Single-Arm, Open-Label, Phase 2 Trial
Anwen Xiong, Shengxiang Ren, Huaimin Liu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 29, 2021
Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study
Xinghao Ai, Yueyin Pan, Jianhua Shi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 6, 2024
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous <i>EGFR</i>-Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial
D Ross Camidge, Jair Bar, Hidehito Horinouchi, et al.
Lancet (London, England)
|
May 29, 2026
Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial
Anwen Xiong, Wenxiu Yao, Wei Zheng, et al.
The Lancet. Oncology
|
June 16, 2025
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial
Caicun Zhou, Ziping Wang, Meili Sun, et al.
Nature Medicine
|
July 11, 2024
Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial
Ying Cheng, Jianhua Chen, Wei Zhang, et al.
Page
of 20